Explore more publications!
Healthy Living South Dakota
Got News to Share?

Healthy Living South Dakota: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living South Dakota.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on November 3, 2025

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
November 3, 2025

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Indeterminate GlobeNewswire
Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate
November 3, 2025

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Indeterminate GlobeNewswire
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
November 3, 2025

SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting

Indeterminate GlobeNewswire
March Biosciences Announces Oral Presentation of MB-105 Interim Phase 2 Clinical Data at American Society of Hematology Annual Meeting
November 3, 2025

March Biosciences Announces Oral Presentation of MB-105 Interim Phase 2 Clinical Data at American Society of Hematology Annual Meeting

Indeterminate GlobeNewswire
Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
November 3, 2025

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

Indeterminate GlobeNewswire
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
November 3, 2025

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

Indeterminate GlobeNewswire
Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting
November 3, 2025

Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

Indeterminate GlobeNewswire
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
November 3, 2025

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Indeterminate GlobeNewswire
Wandercraft Gains Second FDA Indication Extension for Atalante X in Less Than Two Years, Extending Advanced Robotic Rehabilitation for More Patients with Severe Mobility Loss
November 3, 2025

Wandercraft Gains Second FDA Indication Extension for Atalante X in Less Than Two Years, Extending Advanced Robotic Rehabilitation for More Patients with Severe Mobility Loss

Indeterminate GlobeNewswire
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
November 3, 2025

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

Indeterminate GlobeNewswire
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
November 3, 2025

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Indeterminate GlobeNewswire
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
November 3, 2025

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Indeterminate GlobeNewswire
Flare Therapeutics to Participate in Upcoming Investor Conferences in November
November 3, 2025

Flare Therapeutics to Participate in Upcoming Investor Conferences in November

Indeterminate GlobeNewswire
BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS
November 3, 2025

BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS

Indeterminate GlobeNewswire
Solana Company (NASDAQ: HSDT) Releases Investor Update
November 3, 2025

Solana Company (NASDAQ: HSDT) Releases Investor Update

Indeterminate GlobeNewswire
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
November 3, 2025

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

Indeterminate GlobeNewswire
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
November 3, 2025

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Indeterminate GlobeNewswire
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
November 3, 2025

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Indeterminate GlobeNewswire
Vatica Health has merged with Cozeva, expanding leadership in value-based care enablement
November 3, 2025

Vatica Health has merged with Cozeva, expanding leadership in value-based care enablement

Indeterminate GlobeNewswire
Netramark Signs Contract with a Leading Global Biopharmaceutical Company to Enhance Clinical Trial Insights
November 3, 2025

Netramark Signs Contract with a Leading Global Biopharmaceutical Company to Enhance Clinical Trial Insights

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions